Blar i ODA Open Digital Archive på forfatter "Fleischer, Thomas"

Viser treff 1-2 av 2

    • Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab 

      Jabeen, Shakila; Zucknick, Karola Manuela; Nome, Marianne Eikhom; Dannenfelser, Ruth; Fleischer, Thomas; Kumar, Surendra; Luders, Torben; Gythfeldt, Hedda; Troyanskya, Olga; Kyte, Jon A.; Børresen-Dale, Anne-Lise; Naume, Bjørn; Tekpli, Xavier; Engebråten, Olav; Kristensen, Vessela N. (Oncoimmunology;7(11), Journal article; Peer reviewed, 2018-01-08)
      A high concentration of circulating vascular endothelial growth factor (VEGF) in cancer patients is associated with an aggressive tumor phenotype. Here, serum levels of 27 cytokines and blood cell counts were assessed in ...

    • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 

      Møller, Elen Kristine; Nord, Silje; Wedge, David C.; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Genome medicine;10(1), Journal article; Peer reviewed, 2018-11-29)
      Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...